Phases, active trials: Phase 1: 76, Phase 1/2: 6, Phase 2: 46, Phase 2/3: 1, Phase 3: 94, Phase 4: 11, No phase listed: 8
Eli Lilly has transformed its portfolio with two breakthrough platforms: GLP-1/GIP receptor agonists for obesity and diabetes (tirzepatide/Mounjaro, retatrutide, orforglipron) and targeted oncology (Verzenio/abemaciclib in breast cancer, Retevmo/selpercatinib for RET-altered cancers, Jaypirca/pirtobrutinib for B-cell malignancies). The obesity franchise is generating an unprecedented volume of Phase 3 trials across cardiometabolic, liver disease, sleep apnea, kidney disease, and other conditions. In immunology, Omvoh (mirikizumab) for IBD and Olumiant (baricitinib) expansions add breadth beyond oncology and metabolic disease.
- Obesity / metabolic disease (GLP-1/GIP)
- Oncology (breast, RET-altered, BTK)
- Immunology / IBD
- Diabetes
- Alzheimer's disease (donanemab)
- Mounjaro / Zepbound (tirzepatide): GLP-1/GIP dual agonist
- Verzenio (abemaciclib): CDK4/6 inhibitor, breast cancer
- Retevmo (selpercatinib): RET inhibitor, NSCLC/thyroid/other
- Jaypirca (pirtobrutinib): non-covalent BTK inhibitor
- Omvoh (mirikizumab): IL-23p19, IBD
- Donanemab: anti-amyloid beta, Alzheimer's
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| A Study of Sofe-M in Participants With Selected Advanced Solid Tumors NCT06400472 | Primary completion moved at least 2 years 3 months later Primary endpoint(s) modified | Recruiting |
13 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in… NCT06662383 | Nov 2026 · Estimated | Phase 3 |
21 more on the Completions page. See the calendar →
Monitor the Eli Lilly pipeline daily
Get a daily digest when Eli Lilly registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Obesity | 47 |
| Overweight | 40 |
| Healthy | 16 |
| Alzheimer Disease | 15 |
| Diabetes Mellitus, Type 2 | 12 |
| Neoplasm Metastasis | 11 |
| Breast Neoplasms | 10 |
| Carcinoma, Non-Small-Cell Lung | 8 |
Lilly's tirzepatide/GLP-1 platform is the fastest-growing new drug class in history by trial volume. Any company developing obesity, metabolic, or cardiorenal therapeutics needs close visibility into Lilly's expanding label trials. Their oncology pipeline (Verzenio combinations, Retevmo expansions) also generates consistent new Phase 2/3 registrations.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Eli Lilly's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Eli Lilly may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Eli Lilly pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic… NCT07883590 | Not Yet Recruiting | Trial sites expanded: 4 → 7 locations | 2026-11-14 |
| A Study of LY4175408 in Participants With Advanced Cancer NCT07046923 | Active, Not Recruiting | Trial sites reduced: 27 → 24 locations | 2026-11-13 |
| A Study of Tirzepatide Compared With Intensified Conventional Care in Adult… NCT05433584 | Active, Not Recruiting | Results posted: Nov 12, 2026 | 2026-11-13 |
| A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight NCT07232719 | Active, Not Recruiting | Study completion pushed from Jul 2027 to Jun 2028 | 2026-11-11 |
| A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors NCT06561685 | Active, Not Recruiting | Enrollment closed, study ongoing | 2026-11-11 |
Each trial page shows every change DataLookout has recorded for that trial.